Evidence-based follow-up in patients with Hodgkin’s lymphoma and aggressive B-cell non-Hodgkin’s lymphoma

被引：0
作者：
Thomas Spanberger
机构：
[1] Wilhelminen Hospital,Department of Oncology, Hematology and Palliative Care
来源：
memo - Magazine of European Medical Oncology | 2020年 / 13卷
关键词：
DLBCL; Diffuse large b-cell lymphoma; Cardiotoxicity; Imaging; Secondary neoplasm;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In both Hodgkin’s Lymphoma and aggressive Non-Hodgkin’s-Lymphoma, complete remissions and long term survival can be achieved in a high number of patients, especially in those young and fit for intensive chemotherapy. The purpose of this review is to summarize the evidence and recommended follow-up procedures following curative therapy for these entities. After completion of treatment, a tight follow-up schedule is recommended, with history and physical examination being the mainstay of follow-up. There is no convincing evidence of the value of routine imaging for follow-up of lymphoma.
引用
收藏
页码：55 / 59
页数：4
相关论文
共 238 条
[1]  
Engert A(2007)Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: Final results of the GHSG HD7 trial J Clin Oncol 25 3495-3502
[2]  
Franklin J(2012)Dose-intensification in early unfavorable Hodgkin’s lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial J Clin Oncol 30 907-913
[3]  
Eich HT(2003)Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease N Engl J Med 348 2386-2395
[4]  
Brillant C(2002)Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: A randomised trial Lancet 359 2065-2071
[5]  
Sehlen S(2015)Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial Lancet 385 1853-1862
[6]  
Cartoni C(2011)CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group Lancet Oncol 12 1013-1022
[7]  
von Tresckow B(2002)CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235-242
[8]  
Plütschow A(2012)Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: An open-label, randomised, phase 3 trial (DSHNHL 2002-1) Lancet Oncol 13 1250-1259
[9]  
Fuchs M(2010)Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era J Clin Oncol 28 4184-4190
[10]  
Klimm B(2016)Follow-up care for survivors of lymphoma who have received curative-intent treatment Curr Oncol 23 e499-e513
12345678910